Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

6 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
6(100.0%)
6Total
Phase 4(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04762316Phase 4Completed

Composition for Treating Uterine Fibroid (SB-UF)

Role: lead

NCT04770701Phase 4Completed

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes

Role: lead

NCT07084948Phase 4Completed

Using Flavonoids to Kill Hepatitis B Virus

Role: lead

NCT02618148Phase 4Completed

Hormone Estradiol Replacement Therapy Additional Herbals

Role: lead

NCT05399212Phase 4Completed

Composition for Treating Spermatogenesis and Semen Disorders / FPT-20

Role: lead

NCT02620345Phase 4Completed

Fibroids in Women of Reproductive Age and Women Pregnancy

Role: lead

All 6 trials loaded